VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Recombinant Vaccinia-MUC1-B7 Vaccine
Vaccine Information
  • Vaccine Name: Recombinant Vaccinia-MUC1-B7 Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007040
  • Type: Recombinant vector vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: MUC1
  • MUC1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: (Akagi et al., 1997)
    • Detailed Gene Information: Click Here.
  • Cd80 gene engineering:
    • Type: Recombinant protein preparation
    • Description: (Akagi et al., 1997)
    • Detailed Gene Information: Click Here.
  • Preparation: rV-MUC1 was admixed with a recombinant vaccinia virus containing the gene for the murine T-cell costimulatory molecule B7-1 (rV-B7). rV-MUC1 was constructed containing a modified "mini" MUC1 gene containing only 10 tandem repeat sequences to minimize vaccinia-mediated rearrangement (Akagi et al., 1997).
  • Description: This is for Breast Cancer, Ovarian Cancer, Lung Cancer and Pancreatic Cancer. An admixture of recombinant vaccinia virus encoding MUC-1 and recombinant vaccinia virus encoding the murine T-cell co-stimulatory molecule B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone (NCI04) (NCIT_C29409).
Host Response
References
Akagi et al., 1997: Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. Journal of immunotherapy (Hagerstown, Md. : 1997). 1997; 20(1); 38-47. [PubMed: 9101412].
NCIT_C29409: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409]